A new model for health innovation is taking shape at McMaster University.

The NexusHealth Product Pipeline

Wearable tech that tracks your health in real-time

Engineers at NexusHealth are at the forefront of a revolution in health-care technology, developing next-generation wearable biosensors that could redefine personalized health management.

Learn more

An AI-elucidated precision antibiotic for bowel disease

Jon Stokes and his research team have discovered a precision antibiotic that targets the drug-resistant bacteria that drive inflammatory bowel diseases, like Crohn’s. In a global first, the researchers used a new type of AI to successfully predict exactly how the drug would work — shortening the development pathway by several years and reducing the cost of drug discovery by several million dollars.

Learn more

Drugs that block cancer from spreading to the brain

A Nexus-affiliated startup is working on a first-in-class precision medicine that will prevent secondary metastatic brain cancer. The new drug candidate is an innovation that could revolutionize the future of cancer care.

Learn more

A next-gen, needle-free COVID-19 vaccine

NexusHealth researchers are developing a next-generation, needle-free vaccine for COVID-19. This made-at-McMaster vaccine is proven to be more effective at inducing protective immune responses than traditional injections, as it targets the lungs and upper airways — where viruses first enter the body. The new vaccine is administered via a personal inhalation device, and is currently in phase II human trials.

Learn more

New drugs that tackle neuro diseases

With a Nexus-affiliated biotech company, McMaster researchers are using advanced profiling techniques to identify new therapeutic compounds from novel chemistry discovered in a remote rainforest in British Columbia. Already, the team has identified KCB-100, a fungi-derived drug candidate with potent activity against neurological conditions, like depression, anxiety, and Alzheimer’s disease.

Learn more

A new treatment for liver cancer

NexusHealth researchers have developed a promising treatment candidate that helps the immune system attack and destroy liver tumours.

Learn more

State-of-the-art antiviral aptamer technology

Scientists at NexusHealth are designing aptamers — tiny molecules made up of DNA — to stick to specific targets, much like antibodies do. One of the aptamers in development is able to bind to all variants of the virus that causes COVID-19, and thus stands as a promising new treatment option.

Learn more